Drug intelligence / Profile preview

quetiapine + olanzapine + mirtazapine + carbamazepine + sertraline + amitriptyline + chlorpromazine + risperidone

Development stage
Unknown
Lead developer
AstraZeneca
Modality
Small Molecules
Administration
Oral, Intramuscular, Intravenous, Rectal, Subcutaneous
01

Overview

This is a combination of eight psychiatric medications: - **Quetiapine and Olanzapine**: Atypical antipsychotics that work by antagonizing multiple neurotransmitter receptors, including serotonin 5-HT2A and dopamine D2 receptors. - **Mirtazapine**: An atypical antidepressant that enhances noradrenergic and serotonergic neurotransmission through antagonism of central α2-adrenergic autoreceptors. - **Carbamazepine**: An anticonvulsant and mood stabilizer that works by blocking sodium channels. - **Sertraline**: A selective serotonin reuptake inhibitor (SSRI) antidepressant. - **Amitriptyline**: A tricyclic antidepressant that inhibits the reuptake of serotonin and norepinephrine. - **Chlorpromazine**: A first-generation (typical) antipsychotic that blocks dopamine D2 receptors. - **Risperidone**: An atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors. This specific combination is not a standard treatment regimen and would represent polypharmacy with significant risk of drug interactions and additive side effects, including anticholinergic effects, sedation, metabolic effects, and cardiac risks.

02

Targets

HTR2A (Serotonin receptor 5-HT2A)HTR2C (5-hydroxytryptamine 2C receptor)HTR3A (5-hydroxytryptamine receptor 3A)DRD2 (Dopamine D2 Receptor)HRH1 (Histamine H1 Receptor)M1 (Muscarinic acetylcholine receptor M1)NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)NaV (Voltage-gated sodium channels)ADRA1A (α1A)ADRA2A (α2A)mAChR (Muscarinic acetylcholine receptors)

Beyond the preview

Go deeper on quetiapine + olanzapine + mirtazapine + carbamazepine + sertraline + amitriptyline + chlorpromazine + risperidone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on quetiapine + olanzapine + mirtazapine + carbamazepine + sertraline + amitriptyline + chlorpromazine + risperidone.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call